Link Pharma Chem Ltd.

Link Pharma Chem Ltd.

BBSE:LINKPH
24.95
INR
-0.79
(-3.07%)
-0.01EPS
126.33MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
53.13
39.59
27.8
36.26
52.99
55.17
57.36
78.4
120.62
87.28
67.33
57.28
61.77
61.01
Basic EPS, GAAP
1.16
-4.94
1.33
0.51
2.56
1.48
2.14
2.44
4.24
1.47
-3.07
-2.31
0.17
-0.01
Free Cash Flow per Basic Share
-0.66
4.13
-13.2
2.92
5.89
1.09
2.8
6.84
-5.44
-5.85
-2.2
5.47
0.1
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
24.02
18.84
18.86
19.37
22.05
23.38
25.75
28.29
32.6
33.87
30.87
28.51
28.8
- -
Tangible Book Value per Share
24.02
18.84
18.86
19.37
22.05
23.38
25.75
28.29
32.6
33.87
30.87
28.51
28.8
- -
Basic Weighted Avg Shares
4
4
4
4
4
4
4
4
4
4
4
4
4
5
Sales/Revenue/Turnover
236
176
123
161
235
245
255
348
536
388
299
254
274
284
Operating Margin (%)
7.56
-10.14
-5.25
10.99
8.76
6.57
9.75
6.5
4.81
5.65
-5.58
-3.2
3.68
0.84
Depreciation Expense
8
11
9
8
9
9
9
9
9
9
10
9
10
10
Net Income, GAAP
5
-22
6
2
11
7
9
11
19
7
-14
-10
1
- -
Effective Tax Rate (%)
23.32
- -
19.95
53.19
17.2
29.24
34.09
35.36
28.22
26.2
- -
- -
43.08
145.77
Profit Margin (%)
2.19
-12.49
4.8
1.41
4.82
2.69
3.73
3.12
3.51
1.69
-4.56
-4.04
0.28
-0.02
Working Capital
-4
-11
-2
2
22
23
56
59
30
30
5
11
1
- -
LT Debt
51
58
18
12
22
17
32
32
29
20
11
4
7
- -
Total Equity
107
84
84
86
98
104
114
126
145
150
137
127
128
- -
Return on Invested Capital (%)
2.66
- -
5.48
1.6
12.31
6.75
7.85
8.61
10.3
5.91
- -
- -
2.05
- -
Return on Capital (%)
6.56
- -
6.21
4.08
12.46
6.86
8.28
8.68
11.72
5.42
- -
- -
1.96
- -
Return on Common Equity (%)
4.97
-23.07
7.07
2.67
12.34
6.53
8.71
9.04
13.92
4.43
-9.48
-7.79
0.6
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
66
- -
LT Borrowings
- -
7
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
4
Market Capitalization
137
101
126

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
113
- -
Cash, Cash Equivalents & STI
- -
6
- -
Accounts Receivable, Net
- -
53
- -
Inventories
- -
50
- -
Total Current Liabilities
- -
112
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
66
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.62%
0.73%
1%
Free Cash Flow
-48.15%
-136.1%
-98.08%
Net Income, GAAP
-7.65%
-86.45%
-107.49%
Sales/Revenue/Turnover
11.76%
-0.75%
7.85%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
88
48
53
64
254
2026
78
63
67
66
274
2027
88
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.67
-0.69
-1.5
-0.79
-2.31
2026
0.91
0.03
0.15
-0.92
0.17
2027
0.72
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

CEO
Rishikesh Thakur
Full Time Employees
83
Sector
Process industries
Industry
Chemicals: specialty
Address
Plot No. 161/1, 162, GIDC Estate Vadodara GJ India 391 340
IPO Date
Nov 23, 1994
Business
Link Pharma Chem Limited operates within the specialized chemicals sector, producing and supplying a diverse array of organic and drug intermediates. These vital compounds serve a broad spectrum of industries, including pharmaceuticals, agriculture, cosmetics, and veterinary applications. The company places a strong emphasis on custom synthesis and contract manufacturing, providing multi-stage chemical synthesis capabilities for businesses of all sizes. Founded in 1986, this chemical manufacturer is based in Vadodara, India, with its manufacturing facilities situated in Nandesari, Gujarat. Recently, Link Pharma Chem reported its unaudited financial results for the second quarter and first half ended September 30, 2025, showing sales of INR 62.93 million and INR 141.08 million respectively, along with a net income of INR 0.156 million for the quarter and INR 4.17 million for the half-year. The firm distinguishes itself through its technical expertise in handling complex and corrosive reactions, supported by a dedicated research and development team, ensuring products progress from conceptualization to full-scale production.